Linked Life Data

17579864

Source:http://linkedlifedata.com/resource/pubmed/id/17579864

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2008-2-21
pubmed:abstractText
To define the maximum-tolerated dose (MTD) of S-1, given daily for 2 weeks followed by a 1-week rest, with a fixed dose of cisplatin on the initial day, and to determine the activity and safety of this regimen at the recommended dose (RD) when used as first line treatment of advanced gastric cancer (AGC).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0344-5704
pubmed:author
pubmed:issnType
Print
pubmed:volume
61
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
837-45
pubmed:meshHeading
pubmed-meshheading:17579864-Adult, pubmed-meshheading:17579864-Aged, pubmed-meshheading:17579864-Anemia, pubmed-meshheading:17579864-Anorexia, pubmed-meshheading:17579864-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:17579864-Cisplatin, pubmed-meshheading:17579864-Diarrhea, pubmed-meshheading:17579864-Drug Administration Schedule, pubmed-meshheading:17579864-Drug Combinations, pubmed-meshheading:17579864-Female, pubmed-meshheading:17579864-Fever, pubmed-meshheading:17579864-Humans, pubmed-meshheading:17579864-Male, pubmed-meshheading:17579864-Maximum Tolerated Dose, pubmed-meshheading:17579864-Middle Aged, pubmed-meshheading:17579864-Neoplasm Metastasis, pubmed-meshheading:17579864-Neoplasm Recurrence, Local, pubmed-meshheading:17579864-Neutropenia, pubmed-meshheading:17579864-Oxonic Acid, pubmed-meshheading:17579864-Stomach Neoplasms, pubmed-meshheading:17579864-Tegafur
pubmed:year
2008
pubmed:articleTitle
Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer.
pubmed:affiliation
Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Poongnap-dong, Songpa-gu, Seoul, 138-736, South Korea.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II, Clinical Trial, Phase I